In a late-breaking presentation at the International Stroke Conference held in Los Angeles, Recursion announced that cerebral cavernous malformation patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume in the 12 month Phase II study.
The post Recursion Announces Promising Clinical Data on…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
SOUTH JORDAN, Utah, Oct. 13, 2025 /PRNewswire/ — Level Education Group, LLC (“LEG”), a leader in continuing education for mental health and nursing professionals, today announced the acquisition of Triad, a nationally recognized provider of […]
Available to everyone at no cost, the new Articles of Enslavement collection will help descendants of previously enslaved people make family history discoveries LEHI, Utah, June 11, 2024 /PRNewswire/ — Today Ancestry®, the global leader […]
Proposed $50 million 5-year partnerships with HPE would enlarge the U’s computing power using NVIDIA chips, driving new discoveries and innovation in cancer, Alzheimer’s and mental health research SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ […]
Copyright © 2026 Biotech Networks
